Predict your next investment

Other

See what CB Insights has to offer

Investments

3

About Keffi Group

The Keffi Group is a private investment firm based in New York City that focuses exclusively on fundamental, research-driven value investing.

Keffi Group Headquarters Location

New York, New York,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Keffi Group News

VBL Therapeutics Raises $40 Million in Revived Nasdaq IPO

Oct 2, 2014

VBL Therapeutics Raises $40 Million in Revived Nasdaq IPO - After the fiasco of the failed IPO in August, the drug development company scaled down the offering. VBL Therapeutics has raised $40 million at a company value of $120 million in a revived IPO on Nasdaq. In August, the Israeli company, which develops drugs for treating cancer and respiratory illnesses, had raised $65 million on Nasdaq at a company value of $222 million. However, the IPO turned into a fiasco when a principal US investor did not come through with the money, and the company had to cancel the offering and delist five days later. This time around VBL sold 6,666,667 ordinary shares at $6 per share, before underwriting discounts and commissions. On its first day of trading on Nasdaq yesterday, the share price fell 2.5% to $5.85. The share is trading under the VBLT ticker. Deutsche Bank Securities acted as book-running manager for the offering and JMP Securities and Oppenheimer were co-managers. The IPO in August was canceled because one investor, US venture capital fund Keffi Group, headed by founder Jide Zeitlin, did not deliver its money at the closing. The official statement said that the fund had liquidity problems caused by the withdrawal of money deposited with it between the pricing and the closing. It seems that matters are now sorted. Keffi already owned 24% of VBL before the IPO and Zeitlin remains a director on the board. Keffi now plans buying shares worth $24.3 million, about 60% of the offering, and the same book-runners and co-managers remain on board. VBL Therapeutics, founded by CEO Prof. Dror Harats, must now adapt its development plans to the lower sum raised. The company’s drug for treating brain tumors will enter Phase III clinical trials in the first half of 2015, and the funds raised will suffice until the intermediary results in 2016. Good results will enable the company to raise more money. Meanwhile, until further funds can be found, a clinical trial for an immune-inflammatory disease treatment has been put on hold as have plans to build a production plant. Published by Globes [online], Israel business news – www.globes-online.com About the Author

Keffi Group Investments

3 Investments

Keffi Group has made 3 investments. Their latest investment was in Cogentus Pharmaceuticals as part of their Unattributed VC on November 11, 2008.

CBI Logo

Keffi Group Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/21/2008

Unattributed VC

Cogentus Pharmaceuticals

$7.5M

No

12/11/2007

Series C

Subscribe to see more

$99M

Subscribe to see more

0

Unattributed

Subscribe to see more

$99M

Subscribe to see more

0

Date

11/21/2008

12/11/2007

Round

Unattributed VC

Series C

Unattributed

Company

Cogentus Pharmaceuticals

Subscribe to see more

Subscribe to see more

Amount

$7.5M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

0

0

Keffi Group Team

1 Team Member

Keffi Group has 1 team member, including current Founder, Managing Director, Jide Zeitlin.

Name

Work History

Title

Status

Jide Zeitlin

Tapestry, Goldman Sachs, and Coach, Inc.

Founder, Managing Director

Current

Name

Jide Zeitlin

Work History

Tapestry, Goldman Sachs, and Coach, Inc.

Title

Founder, Managing Director

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.